• Skip to main content
  • Skip to footer
cnb1439_3rs-project_nav-ad_v2
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Press releases

May 1, 2019

Sydney’s AXT offers Organ-on-Chip systems in Asia Pacific region

Organ-on-Chip specialist CN Bio has signed a distribution agreement with Sydney-based AXT Pty. Ltd., Australia’s leading supplier of high technology

Category iconPress releases

February 28, 2019

CN Bio to bring 10 organs together on a chip

London Organ-­on-­Chip specialist CN Bio today announced it has secured an exclusive license to technology from the Massachusetts Institute of

Category iconPress releases

November 22, 2018

PhysioMimix® Human 3D Cell Culture wins Lab Innovation 2018 Award

The PhysioMimix® benchtop 3D cell culture system from CN Bio has won the Innovation Award at the UK’s largest laboratory event, held at the NEC

Category iconPress releases

July 19, 2018

CN Bio Innovations’ Board names David Hughes as next Chief Executive Officer

London, UK, 19 July 2018: CN Bio Innovations Limited today announced that its Board of Directors has accepted the resignation of Dr Emma Sceats as CEO

Category iconPress releases

May 23, 2018

CN Bio launches PhysioMimix benchtop Human-Body-on-a-Chip device

London, UK, 23 May 2018: CN Bio Innovations Limited today launched PhysioMimix, a printer-sized device which allows scientist to conduct organ-on-chip

Category iconPress releases

March 14, 2018

CN Bio and MIT announce 10 Organ-On-chip platform: Nature Scientific Reports

Organ-on-Chip specialist CN Bio's microfluidic platform for improving drug evaluation has taken a significant step forward. CN Bio's partners at MIT

Category iconPress releases

November 1, 2017

CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies

London, UK, November 1 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces a research collaboration with global biopharmaceutical

Category iconPress releases

October 26, 2017

FDA signs collaborative agreement with CN Bio Innovations to use Organs-on-Chips to improve drug development and evaluation

London, UK, October 26 2017: CN Bio Innovations Limited announced today that it has entered into a Research Collaboration Agreement with the US Food

Category iconPress releases

October 11, 2017

Innovate UK awards grant to CN Bio Innovations and AstraZeneca to use Organs-on-Chips to evaluate the use of existing drugs to treat fatty liver disease

London, UK, October 11 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces that Innovate UK has awarded the company a £670,000 grant

Category iconPress releases

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio adds computational modelling capabilities to ADME services for enhanced bioavailability profiling September 1, 2025
  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
Cyber Essentials Logo